Willmann S - Search Results

1

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.

Zhu P, Willmann S, Zhou W, Yang H, Michelson AD, McCrindle BW, Li JS, Harris KC, Pina LM, Weber T, Nessel K, Lesko LJ, Kubitza D, Zannikos P. Zhu P, et al. Among authors: willmann s. J Clin Pharmacol. 2022 Feb;62(2):220-231. doi: 10.1002/jcph.1966. Epub 2022 Jan 9. J Clin Pharmacol. 2022. PMID: 34524700 Free PMC article. Clinical Trial.

2

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner FT, Heinig R, Schmeck C, Buehner K. Weber O, et al. Among authors: willmann s. Br J Clin Pharmacol. 2012 Feb;73(2):219-31. doi: 10.1111/j.1365-2125.2011.04064.x. Br J Clin Pharmacol. 2012. PMID: 21762205 Free PMC article.

3

Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, Siegmund HU, Thelen K, Mück W. Willmann S, et al. Clin Pharmacokinet. 2014 Jan;53(1):89-102. doi: 10.1007/s40262-013-0090-5. Clin Pharmacokinet. 2014. PMID: 23912563 Free PMC article. Clinical Trial.

4

Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.

Somani AA, Thelen K, Zheng S, Trame MN, Coboeken K, Meyer M, Schnizler K, Ince I, Willmann S, Schmidt S. Somani AA, et al. Among authors: willmann s. Br J Clin Pharmacol. 2016 Jan;81(1):137-47. doi: 10.1111/bcp.12752. Epub 2015 Oct 30. Br J Clin Pharmacol. 2016. PMID: 26302359 Free PMC article.

5

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.

Willmann S, Zhang L, Frede M, Kubitza D, Mueck W, Schmidt S, Solms A, Yan X, Garmann D. Willmann S, et al. CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):309-320. doi: 10.1002/psp4.12288. Epub 2018 Apr 16. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 29660785 Free PMC article.

6

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.

Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, Monagle P, Male C, Chan A, Kennet G, Martinelli I, Saracco P, Lensing AWA. Kubitza D, et al. Among authors: willmann s. Thromb J. 2018 Dec 4;16:31. doi: 10.1186/s12959-018-0186-0. eCollection 2018. Thromb J. 2018. PMID: 30534007 Free PMC article.

7

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.

Willmann S, Thelen K, Kubitza D, Lensing AWA, Frede M, Coboeken K, Stampfuss J, Burghaus R, Mück W, Lippert J. Willmann S, et al. Thromb J. 2018 Dec 4;16:32. doi: 10.1186/s12959-018-0185-1. eCollection 2018. Thromb J. 2018. PMID: 30534008 Free PMC article.

8

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.

Stass H, Lettieri J, Vanevski KM, Willmann S, James LP, Sullivan JE, Arrieta AC, Bradley JS. Stass H, et al. Among authors: willmann s. J Clin Pharmacol. 2019 May;59(5):654-667. doi: 10.1002/jcph.1358. Epub 2019 Jan 25. J Clin Pharmacol. 2019. PMID: 30681729 Free PMC article. Clinical Trial.

9

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.

Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D. Solms A, et al. Among authors: willmann s. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):805-814. doi: 10.1002/psp4.12444. Epub 2019 Jul 5. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31276324 Free PMC article.

10

Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin.

Willmann S, Frei M, Sutter G, Coboeken K, Wendl T, Eissing T, Lippert J, Stass H. Willmann S, et al. CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):654-663. doi: 10.1002/psp4.12446. Epub 2019 Aug 7. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31310051 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters